Rarity Bioscience provides ultra-sensitive multiplex assays for mutation detection in blood and other liquid biopsies for research, pharma and labs. The superRCA technology is based on padlock probes and rolling circle amplification, enabling extreme sensitivity and specificity, and utilize well established high throughput flow cytometry for the read-out. The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology, and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.
Extern länk för Rarity Bioscience
Dag Hammarskjölds Väg 56E
Uppsala, Uppsala County 752 37, SE
Rarity Bioscience omdelade detta
Rarity Bioscience at ESCCA 2024! Molecular mutation detection using flow cytometry Rarity Bioscience has developed the superRCA assay platform, offering molecular mutation detection using flow cytometry. Advance your research by studying the genetics inside the cells, or even cell free DNA from plasma, bringing a new dimension to Minimal Residual Disease research using flow cytometry. Visit our website: https://lnkd.in/dri9WpXW
🩸September is Leukemia & Lymphoma Awareness Month🩸 Today we would like to highlight the importance of the Leukemia Awareness Month. Leukemia, a cancer of the blood-forming tissues, is accountable for approximately 6% of all cancers worldwide and more than 7% of cancer deaths. Progress and outcome has been greatly improved over the past decade, but there is still a lot of promising research and improvement that can be made. 🔬 Our Contribution: We develop cutting-edge technologies to enhance sensitivity of mutation detection in bone marrow and periphearl blood, particularly targeting improvement within Minimal Residual Disease research. Join us this September in raising awareness and fighting against leukemia and contact us if you are interested in research collaborations - together we can make a difference! #RarityBioscience #superRCA #MRD #ThisIsBloodCancer
Rarity Bioscience omdelade detta
Rarity Bioscience is continuing to grow and is now hiring a Sales Manager and a Field Application Scientist to build the commercial core of the expanding mutation detection start-up in Uppsala. Working at Rarity is rewarding, challenging, and an incredible learning experience—it’s a rollercoaster journey, just like any start-up environment. If you're ready for a role where you can truly make an impact, we'd love to hear from you! 👉 Apply today and be part of our journey towards democratize mutation detection. Sales Manager: https://lnkd.in/gGE4cAkx Field Application Scientist: https://lnkd.in/gB2AXhcd #biotech #hiring #startup #raritybioscience #salesmanager #fieldapplicationscientist #Uppsala
📣 Exciting News! 📣 Rarity Bioscience is proud to be a Gold Sponsor at ESCCA 2024! We are thrilled to announce that the Rarity Bioscience team will be attending ESSCA 2024 as a Gold Sponsor. 👉 Fun Fact: Did you know our Co-Founder & CTO, Lei Chen, won the Best Oral Presentation Award at ESSCA 2023? Don’t miss the chance to visit our booth this year and engage with our team. Looking forward to seeing you at our booth this September! For more information, visit ESCCAs website: https://lnkd.in/dGZwGwGm #RarityBioscience #superRCA #MRD #ESCCA2024 #flowcytometry
🎉 Exciting News! 🎉 We want to welcome Dr. Galina Zheleznyakova to the Rarity Bioscience team as our new scientist R&D. Dr. Zheleznyakova obtained her PhD in Genetics and Biochemistry from St. Petersburg State University. She studied epigenetics and biomarkers of autoimmune diseases at Karolinska Institutet. Previously, she worked at PerkinElmer/Revvity on product development for prenatal diagnostics of chromosomal abnormalities. "I am fascinated by the precision of the Rarity technique and eager to explore new potential applications of the assay within precision diagnostics" Galina Zheleznyakova With her background in biomarker diagnostics and experience with product development based on RCA assays, she will be a valuable addition to the growing R&D team. “I am very happy that Galina is joining us. She will be a great addition to the team and will contribute with her experience in product development and RCA. With her background in academia and the life sciences industry, I am certain that she will help us achieve our mission to improve mutation detection. Welcome to the team, Galina!” Marie Engvall, R&D manager. Please join us in welcoming Dr Galina Zheleznyakova to the Rarity family! 🙌 #RarityBioscience #superRCA #CareerDevelopment #newhiring #welcometotheteam #cancerdiagnosis
We are #hiring! Are you our new Laboratory engineer? Apply or Repost and share! https://lnkd.in/deF2ERaU
We're #hiring a new Senior Scientist - Product development in Uppsala, Uppsala County. Apply today or share this post with your network!
✨ Did you know you can multiplex the superRCA assay for low input cfDNA samples from liquid biopsy? Read the latest publication using superRCA! 🔍🩸 Sensitive & Specific Analyses of CRC Recurrence through Multiplex superRCA Mutation Detection in Blood Plasma In a groundbreaking study, researchers from Professor Tobias Sjöblom and Professor Ulf Landegren's groups at Uppsala University have successfully demonstrated the superRCA assay's multiplexing ability. This innovation is a game-changer for studying measurable residual disease (MRD) in Colorectal Cancer patients, providing a powerful tool for non-invasive diagnostic biomarkers from plasma samples. 🧬📊 🌟The team evaluated tumor-specific mutations in 25 patients from the Uppsala-Umeå Comprehensive Cancer Consortium (U-CAN), The lower limit of detection for most sequence variants was in the range of 10−5, while when analyzing cfDNA from plasma with a typical input of 33 ng, the practical detection limit was ~10−4 or 0.01% mutant allele frequency. 📖 Read the full study here: https://lnkd.in/dJV9PgBK Additionally, we have a curated list of publications with a focus on AML. Don't forget to check it out on our website and leave a comment if you enjoyed the read! 📝💬 MDPI #RarityBioscience #superRCA #NewPublication #MRD
📣 Exciting News! 📣 Rarity Bioscience is proud to announce that we have received funding approval through the Bio-X accelerator. This support will significantly enhance our innovative projects and expand our impact in the life sciences industry. We extend our heartfelt thanks to the Bio-X Advisory Board and #Tillväxtverket for believing in our vision and providing this valuable opportunity. Together, we are paving the way for groundbreaking advancements in biosciences. #LifeSciences #BioTech #Innovation #BioXAccelerator #RarityBioscience
🗞 GenomeWeb just published an article on superRCA and our work and development in the MRD space. The article describes the elegancy of the allele distinction in a very intuitive way and also covers future outlooks and applications. Enjoy! 🌞 #MRD #liquidbiopsy #precisiondiagnostics #Cancer #startup #diagnostics
The Swedish company is scaling up the production of targeted mutation assay kits and plans to release some of them for research use by the end of the year.
Senaste finansieringsrunda
Kapital536 453,00 US$
Investerare